0001192482-19-000424.txt : 20191113
0001192482-19-000424.hdr.sgml : 20191113
20191113205222
ACCESSION NUMBER: 0001192482-19-000424
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191108
FILED AS OF DATE: 20191113
DATE AS OF CHANGE: 20191113
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Azarbarzin Kurt
CENTRAL INDEX KEY: 0001792303
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39130
FILM NUMBER: 191215980
MAIL ADDRESS:
STREET 1: C/O TELA BIO, INC.
STREET 2: 1 GREAT VALLEY PARKWAY, SUITE 24
CITY: MALVERN
STATE: PA
ZIP: 19355
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TELA Bio, Inc.
CENTRAL INDEX KEY: 0001561921
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 455320061
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 GREAT VALLEY PARKWAY, SUITE 24
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: 484-320-2930
MAIL ADDRESS:
STREET 1: 1 GREAT VALLEY PARKWAY, SUITE 24
CITY: MALVERN
STATE: PA
ZIP: 19355
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2019-11-08
0001561921
TELA Bio, Inc.
TELA
0001792303
Azarbarzin Kurt
C/O HIGHCAPE PARTNERS QP, L.P.
10751 FALLS ROAD, SUITE 300
BALTIMORE
MD
21093
1
0
0
0
Common Stock
2019-11-08
4
P
0
10220
13.00
A
12675
I
By HighCape Partners, L.P.
Common Stock
2019-11-08
4
P
0
75901
13.00
A
260808
I
By HighCape Partners QP, L.P.
Common Stock
2019-11-13
4
C
0
269
A
12944
I
By HighCape Partners, L.P.
Common Stock
2019-11-13
4
C
0
2931
A
15875
I
By HighCape Partners, L.P.
Common Stock
2019-11-13
4
C
0
19982
A
280790
I
By HighCape Partners QP, L.P.
Common Stock
2019-11-13
4
C
0
217816
A
498606
I
By HighCape Partners QP, L.P.
Series A Preferred Stock
2019-11-13
4
C
0
493357
0
D
Common Stock
19982
0
I
By HighCape Partners QP, L.P.
Series A Preferred Stock
2019-11-13
4
C
0
6643
0
D
Common Stock
269
0
I
By HighCape Partners, L.P.
Series B Preferred Stock
2019-11-13
4
C
0
5377928
0
D
Common Stock
217816
0
I
By HighCape Partners QP, L.P.
Series B Preferred Stock
2019-11-13
4
C
0
72417
0
D
Common Stock
2931
0
I
By HighCape Partners, L.P.
Warrant (right to buy)
1.16
2019-11-13
4
C
0
123653
0
D
2017-01-18
2027-01-18
Series B Preferred Stock
123653
0
I
By HighCape Partners QP, L.P.
Warrant (right to buy)
28.65
2019-11-13
4
C
0
123653
0
A
2017-11-13
2027-01-18
Common Stock
5008
123653
I
By HighCape Partners QP, L.P.
Warrant (right to buy)
1.16
2019-11-13
4
C
0
1665
0
D
2017-01-18
2027-01-18
Series B Preferred Stock
1665
0
I
By HighCape Partners, L.P.
Warrant (right to buy)
28.65
2019-11-13
4
C
0
1665
0
A
2019-11-13
2027-01-18
Common Stock
67
1665
I
By HighCape Partners, L.P.
Reflects 2,455 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
Reflects 183,907 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.
Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.
/s/ Nora Brennan as attorney-in-fact for Matt Zuga
2019-11-13